Zacks Research Reduces Earnings Estimates for AngioDynamics

AngioDynamics, Inc. (NASDAQ:ANGO) – Equities researchers at Zacks Research lowered their Q2 2025 EPS estimates for AngioDynamics in a research note issued to investors on Wednesday, October 23rd. Zacks Research analyst D. Dey now forecasts that the medical instruments supplier will post earnings per share of ($0.12) for the quarter, down from their previous estimate of ($0.10). The consensus estimate for AngioDynamics’ current full-year earnings is ($0.41) per share. Zacks Research also issued estimates for AngioDynamics’ Q4 2025 earnings at ($0.08) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.12) EPS and FY2027 earnings at ($0.16) EPS.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.04. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The company had revenue of $67.50 million for the quarter, compared to analysts’ expectations of $67.93 million. During the same period last year, the firm earned ($0.12) earnings per share. The business’s revenue for the quarter was down 14.2% on a year-over-year basis.

A number of other brokerages have also recently issued reports on ANGO. HC Wainwright reissued a “buy” rating and issued a $14.00 price objective on shares of AngioDynamics in a research note on Friday, October 4th. Canaccord Genuity Group decreased their price objective on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, October 4th.

AngioDynamics Price Performance

Shares of NASDAQ:ANGO opened at $6.73 on Friday. The company’s 50 day simple moving average is $7.15 and its 200 day simple moving average is $6.68. The stock has a market capitalization of $269.57 million, a price-to-earnings ratio of -1.39 and a beta of 0.65. AngioDynamics has a 1 year low of $5.26 and a 1 year high of $8.25.

Insider Buying and Selling at AngioDynamics

In related news, CEO James C. Clemmer bought 20,000 shares of the business’s stock in a transaction on Monday, October 7th. The shares were purchased at an average price of $6.03 per share, for a total transaction of $120,600.00. Following the completion of the transaction, the chief executive officer now directly owns 681,582 shares of the company’s stock, valued at approximately $4,109,939.46. This represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders have purchased 22,568 shares of company stock worth $135,847 over the last quarter. Corporate insiders own 5.10% of the company’s stock.

Institutional Trading of AngioDynamics

Hedge funds have recently added to or reduced their stakes in the stock. Quarry LP lifted its holdings in shares of AngioDynamics by 75.1% during the second quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 2,594 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of AngioDynamics by 9.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 33,772 shares of the medical instruments supplier’s stock worth $199,000 after purchasing an additional 2,821 shares during the period. State Board of Administration of Florida Retirement System lifted its holdings in shares of AngioDynamics by 44.1% during the first quarter. State Board of Administration of Florida Retirement System now owns 15,627 shares of the medical instruments supplier’s stock worth $92,000 after purchasing an additional 4,780 shares during the period. CWM LLC lifted its holdings in shares of AngioDynamics by 981.3% during the third quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock worth $76,000 after purchasing an additional 8,832 shares during the period. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in shares of AngioDynamics during the third quarter worth $86,000. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.